Nyxoah (NASDAQ:NYXH – Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Nyxoah to post earnings of ($0.3510) per share and revenue of $11.00 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
Nyxoah (NASDAQ:NYXH – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.20). Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. The firm had revenue of $8.76 million during the quarter, compared to analyst estimates of $8.64 million. On average, analysts expect Nyxoah to post ($1.46) EPS for the current fiscal year and ($0.80) EPS for the next fiscal year.
Nyxoah Stock Performance
Shares of NASDAQ NYXH opened at $0.87 on Wednesday. The company’s fifty day moving average price is $1.32 and its 200 day moving average price is $2.48. Nyxoah has a 1 year low of $0.80 and a 1 year high of $5.92. The company has a market capitalization of $33.72 million, a PE ratio of -0.35 and a beta of 1.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.31 and a current ratio of 2.38.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. Robert W. Baird set a $2.31 price objective on shares of Nyxoah in a report on Thursday, August 6th. Raymond James Financial set a $3.00 target price on shares of Nyxoah in a research note on Tuesday, October 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Nyxoah in a research report on Wednesday, August 19th. Wall Street Zen cut Nyxoah from a “hold” rating to a “sell” rating in a research report on Sunday, August 9th. Finally, Piper Sandler restated an “overweight” rating and issued a $6.00 price target (down from $7.00) on shares of Nyxoah in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $3.55.
Check Out Our Latest Research Report on NYXH
Nyxoah Company Profile
Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA), a common sleep-related breathing disorder. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares trade on the Nasdaq under the symbol NYXH.
Nyxoah’s principal product is the Genio system, an implantable, rechargeable device designed to treat OSA through hypoglossal nerve stimulation. The system is intended to help maintain an open airway during sleep by stimulating the nerves that control the tongue and related upper-airway muscles.
Read More
- Five stocks we like better than Nyxoah
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
